Advanced Therapies Week 2022 | LMY-920 in non-Hodgkin lymphoma

Patients with B-cell non-Hodgkin lymphoma (NHL) can progress on current anti-CD19 chimeric antigen receptor (CAR) T-cell therapies due to antigen escape. Jeff Liter, MBA, Luminary Therapeutics, Minneapolis, MN, provides an overview of LMY-920, a B-cell activating factor (BAFF)-directed CAR-T therapy, which consists of three different antigens on the CAR T-cell. The three markers prevents antigen escape and the therapy additionally contains no foreign linkers, reducing immunogenicity. An Investigational New Drug Application (IND) will be imminently filed for LMY-920, with the therapy aiming to target NHL and mantle cell lymphoma (MCL). This interview took place at Advanced Therapies Week 2022.